Amylyx Pharmaceuticals Files 8-K on Exit/Disposal Activities
Ticker: AMLX · Form: 8-K · Filed: Apr 4, 2024 · CIK: 1658551
Sentiment: neutral
Topics: restructuring, disposal, regulatory-filing
TL;DR
Amylyx 8-K: Costs related to exit/disposal activities reported. Details scarce.
AI Summary
Amylyx Pharmaceuticals, Inc. filed an 8-K on April 4, 2024, reporting on events that occurred on April 3, 2024. The filing indicates costs associated with exit or disposal activities, a Regulation FD disclosure, and other events, along with financial statements and exhibits. Specific details regarding the nature or financial impact of these activities are not provided in the excerpt.
Why It Matters
This filing signals potential restructuring or divestment activities within Amylyx Pharmaceuticals, which could impact its operational focus and financial outlook.
Risk Assessment
Risk Level: medium — The filing mentions 'Cost Associated with Exit or Disposal Activities,' which can indicate significant operational changes or financial restructuring that may carry inherent risks.
Key Players & Entities
- Amylyx Pharmaceuticals, Inc. (company) — Registrant
- April 3, 2024 (date) — Earliest event reported
- April 4, 2024 (date) — Date of report
- 001-41199 (company) — SEC File Number
- 46-4600503 (company) — IRS Employer Identification No.
- 43 Thorndike St. (location) — Principal executive offices address
- Cambridge, MA (location) — Principal executive offices city and state
- 02141 (location) — Principal executive offices zip code
- (617) 682-0917 (phone_number) — Registrant's telephone number
FAQ
What specific exit or disposal activities are being reported by Amylyx Pharmaceuticals?
The provided excerpt does not specify the nature of the 'Cost Associated with Exit or Disposal Activities'.
What is the financial impact of these exit or disposal activities?
The excerpt does not provide any financial figures related to the costs associated with exit or disposal activities.
When did the earliest reported event in this 8-K filing occur?
The earliest reported event occurred on April 3, 2024.
What is the SEC file number for Amylyx Pharmaceuticals?
The SEC file number for Amylyx Pharmaceuticals, Inc. is 001-41199.
Where are Amylyx Pharmaceuticals' principal executive offices located?
Amylyx Pharmaceuticals' principal executive offices are located at 43 Thorndike St., Cambridge, MA 02141.
Filing Stats: 1,194 words · 5 min read · ~4 pages · Grade level 13 · Accepted 2024-04-04 07:10:54
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share AMLX Nasdaq Glo
- $19 million — erance-related charges of approximately $19 million. The Company is also evaluating its i
Filing Documents
- d780895d8k.htm (8-K) — 31KB
- d780895dex991.htm (EX-99.1) — 21KB
- 0001193125-24-086609.txt ( ) — 179KB
- amlx-20240403.xsd (EX-101.SCH) — 3KB
- amlx-20240403_lab.xml (EX-101.LAB) — 17KB
- amlx-20240403_pre.xml (EX-101.PRE) — 11KB
- d780895d8k_htm.xml (XML) — 3KB
Forward-Looking Statements
Forward-Looking Statements looking statements in this Current Report on Form 8-K are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. Risks that contribute to the uncertain nature of the forward-looking statements include the risks and uncertainties set forth in Amylyx' United States Securities and Exchange Commission (SEC) filings, includ
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits . Exhibit Number Description 99.1 Press Release of the Company, dated April 4, 2024 104 Cover Page Interactive Data File (embedded with the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. AMYLYX PHARMACEUTICALS, INC. Date: April 4, 2024 By: /s/ James M. Frates James M. Frates Chief Financial Officer